S&P 500   4,534.97 (+0.34%)
DOW   35,598.31 (+0.40%)
QQQ   374.75 (-0.19%)
AAPL   148.89 (+0.09%)
MSFT   307.42 (-0.26%)
FB   340.66 (+0.20%)
GOOGL   2,838.39 (-0.92%)
TSLA   865.67 (+0.16%)
AMZN   3,417.05 (-0.79%)
NVDA   220.29 (-1.17%)
BABA   177.54 (+0.31%)
NIO   39.68 (-0.87%)
CGC   14.20 (-0.98%)
GE   105.39 (+0.63%)
AMD   116.25 (-0.07%)
MU   68.38 (+1.20%)
T   25.96 (+1.45%)
F   15.94 (+3.37%)
ACB   7.60 (+2.01%)
DIS   170.62 (-0.33%)
PFE   42.83 (+1.76%)
BA   216.63 (+0.31%)
AMC   40.89 (+0.22%)
S&P 500   4,534.97 (+0.34%)
DOW   35,598.31 (+0.40%)
QQQ   374.75 (-0.19%)
AAPL   148.89 (+0.09%)
MSFT   307.42 (-0.26%)
FB   340.66 (+0.20%)
GOOGL   2,838.39 (-0.92%)
TSLA   865.67 (+0.16%)
AMZN   3,417.05 (-0.79%)
NVDA   220.29 (-1.17%)
BABA   177.54 (+0.31%)
NIO   39.68 (-0.87%)
CGC   14.20 (-0.98%)
GE   105.39 (+0.63%)
AMD   116.25 (-0.07%)
MU   68.38 (+1.20%)
T   25.96 (+1.45%)
F   15.94 (+3.37%)
ACB   7.60 (+2.01%)
DIS   170.62 (-0.33%)
PFE   42.83 (+1.76%)
BA   216.63 (+0.31%)
AMC   40.89 (+0.22%)
S&P 500   4,534.97 (+0.34%)
DOW   35,598.31 (+0.40%)
QQQ   374.75 (-0.19%)
AAPL   148.89 (+0.09%)
MSFT   307.42 (-0.26%)
FB   340.66 (+0.20%)
GOOGL   2,838.39 (-0.92%)
TSLA   865.67 (+0.16%)
AMZN   3,417.05 (-0.79%)
NVDA   220.29 (-1.17%)
BABA   177.54 (+0.31%)
NIO   39.68 (-0.87%)
CGC   14.20 (-0.98%)
GE   105.39 (+0.63%)
AMD   116.25 (-0.07%)
MU   68.38 (+1.20%)
T   25.96 (+1.45%)
F   15.94 (+3.37%)
ACB   7.60 (+2.01%)
DIS   170.62 (-0.33%)
PFE   42.83 (+1.76%)
BA   216.63 (+0.31%)
AMC   40.89 (+0.22%)
S&P 500   4,534.97 (+0.34%)
DOW   35,598.31 (+0.40%)
QQQ   374.75 (-0.19%)
AAPL   148.89 (+0.09%)
MSFT   307.42 (-0.26%)
FB   340.66 (+0.20%)
GOOGL   2,838.39 (-0.92%)
TSLA   865.67 (+0.16%)
AMZN   3,417.05 (-0.79%)
NVDA   220.29 (-1.17%)
BABA   177.54 (+0.31%)
NIO   39.68 (-0.87%)
CGC   14.20 (-0.98%)
GE   105.39 (+0.63%)
AMD   116.25 (-0.07%)
MU   68.38 (+1.20%)
T   25.96 (+1.45%)
F   15.94 (+3.37%)
ACB   7.60 (+2.01%)
DIS   170.62 (-0.33%)
PFE   42.83 (+1.76%)
BA   216.63 (+0.31%)
AMC   40.89 (+0.22%)
LON:AZN

AstraZeneca Share Forecast, Price & News

GBX 8,768
+29.00 (+0.33 %)
(As of 10/20/2021 04:35 PM ET)
Add
Compare
Today's Range
8,732
8,817
50-Day Range
8,063
9,003
52-Week Range
6,736
9,081
Volume939,083 shs
Average Volume2.27 million shs
Market Capitalization£135.83 billion
P/E Ratio41.52
Dividend Yield2.32%
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.


AstraZeneca logo

About AstraZeneca

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
76,100
Year Founded
N/A

Sales & Book Value

Annual Sales
£29.53 billion
Cash Flow
GBX 1,187.54 per share
Book Value
GBX 1,194.80 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
1,549,136,000
Market Cap
£135.83 billion
Next Earnings Date
11/12/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.66 out of 5 stars

Analyst Opinion: 2.4Community Rank: 4.3Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












AstraZeneca (LON:AZN) Frequently Asked Questions

Is AstraZeneca a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AstraZeneca stock.
View analyst ratings for AstraZeneca
or view top-rated stocks.

What stocks does MarketBeat like better than AstraZeneca?

Wall Street analysts have given AstraZeneca a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AstraZeneca wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for AstraZeneca
.

How has AstraZeneca's stock been impacted by COVID-19 (Coronavirus)?

AstraZeneca's stock was trading at GBX 6,955 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AZN stock has increased by 26.1% and is now trading at GBX 8,768.
View which stocks have been most impacted by COVID-19
.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a dividend on Thursday, July 29th. Investors of record on Thursday, August 12th will be given a dividend of GBX 64.80 per share on Monday, September 13th. This represents a yield of 0.78%. The ex-dividend date of this dividend is Thursday, August 12th. The official announcement can be accessed at this link.
View AstraZeneca's dividend history
.

Is AstraZeneca a good dividend stock?

AstraZeneca pays an annual dividend of GBX 2.84 per share and currently has a dividend yield of 2.32%. The dividend payout ratio of AstraZeneca is 1.35%. This payout ratio is at a healthy, sustainable level, below 75%.
View AstraZeneca's dividend history.

What price target have analysts set for AZN?

14 analysts have issued 1-year target prices for AstraZeneca's stock. Their forecasts range from GBX 6,950 to £105. On average, they expect AstraZeneca's share price to reach GBX 9,635 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price.
View analysts' price targets for AstraZeneca
or view top-rated stocks among Wall Street analysts.

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:
  • Mr. Pascal Soriot D.V.M., M.B.A., CEO & Exec. Director (Age 62, Pay $4.39M)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 69, Pay $2.45M)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 50)
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Exec. VP of HR & Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer
  • Dr. Menelas Pangalos, Exec. Vice-Pres of BioPharmaceuticals R&D
  • Dr. Ruud Dobber, Exec. Vice-Pres of BioPharmaceuticals Bus. Unit
  • Dr. Susan Mary Galbraith M.D., Ph.D., Exec. VP of Oncology R&D (Age 55)
  • Dr. David B. Goldstein Ph.D., Chief Adviser

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).

What is AstraZeneca's stock symbol?

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately GBX 8,768.

How much money does AstraZeneca make?

AstraZeneca has a market capitalization of £135.83 billion and generates £29.53 billion in revenue each year.

How many employees does AstraZeneca have?

AstraZeneca employs 76,100 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

Where are AstraZeneca's headquarters?

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.


This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.